Methylphenidate Hydrochloride Patent Expiration
Methylphenidate Hydrochloride was first introduced by Sandoz Inc
Methylphenidate Hydrochloride Patents
Given below is the list of patents protecting Methylphenidate Hydrochloride, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Adhansia Xr | US10722473 | Methods and compositions particularly for treatment of attention deficit disorder | Nov 19, 2038 | Purdue Pharma Lp |
| Relexxii | US10265308 | Dose-dumping resistant controlled release dosage form | Feb 03, 2037 | Osmotica Pharm Us |
| Relexxii | US10695336 | Dose-dumping resistant controlled release dosage form | Feb 03, 2037 | Osmotica Pharm Us |
| Relexxii | US9707217 | SYSTEMS FOR DETERMINING FAULT LOCATION ON POWER DISTRIBUTION LINES | Feb 03, 2037 | Osmotica Pharm Us |
| Relexxii | US9827234 | APPARATUS AND METHOD ARRANGED TO PROVIDE CONTROLLABLE WATER TREATMENT CUSTOMIZED TO THE CONDITIONS OF WATER SUPPLIED TO A BEVERAGE DISPENSER | Feb 03, 2037 | Osmotica Pharm Us |
| Relexxii | US9855258 | Dose-dumping resistant controlled release dosage form | Feb 03, 2037 | Osmotica Pharm Us |
| Adhansia Xr | US10111839 | Methods and compositions particularly for treatment of attention deficit disorder | Oct 30, 2035 | Purdue Pharma Lp |
| Adhansia Xr | US10292938 | Methods and compositions particularly for treatment of attention deficit disorder | Oct 30, 2035 | Purdue Pharma Lp |
| Adhansia Xr | US10292939 | Methods and compositions particularly for treatment of attention deficit disorder | Oct 30, 2035 | Purdue Pharma Lp |
| Adhansia Xr | US10449159 | Methods and compositions particularly for treatment of attention deficit disorder | Oct 30, 2035 | Purdue Pharma Lp |
| Adhansia Xr | US10500162 | Methods and compositions particularly for treatment of attention deficit disorder | Oct 30, 2035 | Purdue Pharma Lp |
| Adhansia Xr | US10507186 | Methods and compositions particularly for treatment of attention deficit disorder | Oct 30, 2035 | Purdue Pharma Lp |
| Adhansia Xr | US10512612 | Methods and compositions particularly for treatment of attention deficit disorder | Oct 30, 2035 | Purdue Pharma Lp |
| Adhansia Xr | US10512613 | Methods and compositions particularly for treatment of attention deficit disorder | Oct 30, 2035 | Purdue Pharma Lp |
| Adhansia Xr | US10568841 | Methods and compositions particularly for treatment of attention deficit disorder | Oct 30, 2035 | Purdue Pharma Lp |
| Adhansia Xr | US10688060 | Methods and compositions particularly for treatment of attention deficit disorder | Oct 30, 2035 | Purdue Pharma Lp |
| Adhansia Xr | US9974752 | Methods and compositions particularly for treatment of attention deficit disorder | Oct 30, 2035 | Purdue Pharma Lp |
| Quillichew Er | US10857143 | Methylphenidate extended release chewable tablet | Aug 14, 2033 | Nextwave Pharms |
| Quillichew Er | US11103494 | Methylphenidate extended release chewable tablet | Aug 14, 2033 | Nextwave Pharms |
| Quillichew Er | US11103495 | Methylphenidate extended release chewable tablet | Aug 14, 2033 | Nextwave Pharms |
| Quillichew Er | US11633389 | Methylphenidate extended release chewable tablet | Aug 14, 2033 | Nextwave Pharms |
| Quillichew Er | US8999386 | Methylphenidate extended release chewable tablet | Aug 14, 2033 | Nextwave Pharms |
| Quillichew Er | US9295642 | Methylphenidate extended release chewable tablet | Aug 14, 2033 | Nextwave Pharms |
| Quillichew Er | US9545399 | Methylphenidate extended release chewable tablet | Aug 14, 2033 | Nextwave Pharms |
| Quillichew Er | US9844544 | Methylphenidate extended release chewable tablet | Aug 14, 2033 | Nextwave Pharms |
| Jornay Pm | US10182995 | Compositions for treatment of attention deficit hyperactivity disorder | Mar 23, 2032 | Ironshore Pharms |
| Jornay Pm | US10292937 | Methods of treatment of attention deficit hyperactivity disorder | Mar 23, 2032 | Ironshore Pharms |
| Jornay Pm | US10617651 | Compositions for treatment of attention deficit hyperactivity disorder | Mar 23, 2032 | Ironshore Pharms |
| Jornay Pm | US10881618 | Compositions for treatment of attention deficit hyperactivity disorder | Mar 23, 2032 | Ironshore Pharms |
| Jornay Pm | US10905652 | Compositions for treatment of attention deficit hyperactivity disorder | Mar 23, 2032 | Ironshore Pharms |
| Jornay Pm | US11241391 | Compositions for treatment of attention deficit hyperactivity disorder | Mar 23, 2032 | Ironshore Pharms |
| Jornay Pm | US11241392 | Compositions for treatment of attention deficit hyperactivity disorder | Mar 23, 2032 | Ironshore Pharms |
| Jornay Pm | US11911518 | Compositions for treatment of attention deficit hyperactivity disorder | Mar 23, 2032 | Ironshore Pharms |
| Jornay Pm | US8916588 | Methods for treatment of attention deficit hyperactivity disorder | Mar 23, 2032 | Ironshore Pharms |
| Jornay Pm | US8927010 | Compositions for treatment of attention deficit hyperactivity disorder | Mar 23, 2032 | Ironshore Pharms |
| Jornay Pm | US9023389 | Compositions for treatment of attention deficit hyperactivity disorder | Mar 23, 2032 | Ironshore Pharms |
| Jornay Pm | US9028868 | Methods and compositions for treatment of attention deficit disorder | Mar 23, 2032 | Ironshore Pharms |
| Jornay Pm | US9034902 | Methods for treatment of attention deficit hyperactivity disorder | Mar 23, 2032 | Ironshore Pharms |
| Jornay Pm | US9283214 | Compositions for treatment of attention deficit hyperactivity disorder | Mar 23, 2032 | Ironshore Pharms |
| Jornay Pm | US9498447 | Compositions for treatment of attention deficit hyperactivity disorder | Mar 23, 2032 | Ironshore Pharms |
| Jornay Pm | US9603809 | Methods of treatment of attention deficit hyperactivity disorder | Mar 23, 2032 | Ironshore Pharms |
| Quillichew Er | US8287903 | Orally effective methylphenidate extended release powder and aqueous suspension product | Feb 15, 2031 | Nextwave Pharms |
| Quillivant Xr | US8287903 | Orally effective methylphenidate extended release powder and aqueous suspension product | Feb 15, 2031 | Nextwave |
| Quillivant Xr | US8465765 | Orally effective methylphenidate extended release powder and aqueous suspension product | Feb 15, 2031 | Nextwave |
| Quillivant Xr | US8563033 | Orally effective methylphenidate extended release powder and aqueous suspension product | Feb 15, 2031 | Nextwave |
| Quillivant Xr | US8778390 | Orally effective methylphenidate extended release powder and aqueous suspension product | Feb 15, 2031 | Nextwave |
| Quillivant Xr | US8956649 | Orally effective methylphenidate extended release powder and aqueous suspension product | Feb 15, 2031 | Nextwave |
| Quillivant Xr | US9040083 | Orally effective methylphenidate extended release powder and aqueous suspension product | Feb 15, 2031 | Nextwave |
| Quillivant Xr | US8062667 | Modified release formulations containing drug-ion exchange resin complexes | Mar 29, 2029 | Nextwave |
| Quillichew Er | US8202537 | Modified release formulations containing drug-ion exchange resin complexes | Mar 15, 2027 | Nextwave Pharms |
| Methylin | US7691880 | Methylphenidate solution and associated methods of administration and production |
Oct 07, 2024
(Expired) | Specgx Llc |
| Metadate Cd | US6344215 | Methylphenidate modified release formulations |
Oct 27, 2020
(Expired) | Aytu Biopharma |
| Aptensio Xr |
US10039719 (Pediatric) | Methods of treating attention deficit hyperactivity disorder |
Jun 16, 2020
(Expired) | Rhodes Pharms |
| Aptensio Xr |
US6419960 (Pediatric) | Controlled release formulations having rapid onset and rapid decline of effective plasma drug concentrations |
Jun 16, 2020
(Expired) | Rhodes Pharms |
| Aptensio Xr |
US7083808 (Pediatric) | Controlled/modified release oral methylphenidate formulations |
Jun 16, 2020
(Expired) | Rhodes Pharms |
| Aptensio Xr |
US7247318 (Pediatric) | Controlled release formulations having rapid onset and rapid decline of effective plasma drug concentrations |
Jun 16, 2020
(Expired) | Rhodes Pharms |
| Aptensio Xr |
US7438930 (Pediatric) | Controlled release formulations having rapid onset and rapid decline of effective plasma drug concentrations |
Jun 16, 2020
(Expired) | Rhodes Pharms |
| Aptensio Xr |
US8580310 (Pediatric) | Controlled release formulations having rapid onset and rapid decline of effective plasma drug concentrations |
Jun 16, 2020
(Expired) | Rhodes Pharms |
| Aptensio Xr |
US9066869 (Pediatric) | Controlled release formulations having rapid onset and rapid decline of effective plasma drug concentrations |
Jun 16, 2020
(Expired) | Rhodes Pharms |
| Aptensio Xr |
US9801823 (Pediatric) | Controlled release formulations having rapid onset and rapid decline of effective plasma drug concentrations |
Jun 16, 2020
(Expired) | Rhodes Pharms |
| Aptensio Xr | US10039719 | Methods of treating attention deficit hyperactivity disorder |
Dec 16, 2019
(Expired) | Rhodes Pharms |
| Aptensio Xr | US10463624 | Controlled release formulations |
Dec 16, 2019
(Expired) | Rhodes Pharms |
| Aptensio Xr | US6419960 | Controlled release formulations having rapid onset and rapid decline of effective plasma drug concentrations |
Dec 16, 2019
(Expired) | Rhodes Pharms |
| Aptensio Xr | US7083808 | Controlled/modified release oral methylphenidate formulations |
Dec 16, 2019
(Expired) | Rhodes Pharms |
| Aptensio Xr | US7247318 | Controlled release formulations having rapid onset and rapid decline of effective plasma drug concentrations |
Dec 16, 2019
(Expired) | Rhodes Pharms |
| Aptensio Xr | US7438930 | Controlled release formulations having rapid onset and rapid decline of effective plasma drug concentrations |
Dec 16, 2019
(Expired) | Rhodes Pharms |
| Aptensio Xr | US8580310 | Controlled release formulations having rapid onset and rapid decline of effective plasma drug concentrations |
Dec 16, 2019
(Expired) | Rhodes Pharms |
| Aptensio Xr | US9066869 | Controlled release formulations having rapid onset and rapid decline of effective plasma drug concentrations |
Dec 16, 2019
(Expired) | Rhodes Pharms |
| Aptensio Xr | US9801823 | Controlled release formulations having rapid onset and rapid decline of effective plasma drug concentrations |
Dec 16, 2019
(Expired) | Rhodes Pharms |
| Ritalin La | US6228398 | Multiparticulate modified release composition |
Nov 01, 2019
(Expired) | Sandoz |
| Concerta |
US6919373 (Pediatric) | Methods and devices for providing prolonged drug therapy |
Jan 31, 2018
(Expired) | Janssen Pharms |
| Concerta |
US6930129 (Pediatric) | Methods and devices for providing prolonged drug therapy |
Jan 31, 2018
(Expired) | Janssen Pharms |
| Concerta |
US8163798 (Pediatric) | Methods and devices for providing prolonged drug therapy |
Jan 31, 2018
(Expired) | Janssen Pharms |
| Concerta |
US8629179 (Pediatric) | Methods and devices for providing prolonged drug therapy |
Jan 31, 2018
(Expired) | Janssen Pharms |
| Concerta |
US9000038 (Pediatric) | Methods and devices for providing prolonged drug therapy |
Jan 31, 2018
(Expired) | Janssen Pharms |
| Concerta | US6919373 | Methods and devices for providing prolonged drug therapy |
Jul 31, 2017
(Expired) | Janssen Pharms |
| Concerta | US6930129 | Methods and devices for providing prolonged drug therapy |
Jul 31, 2017
(Expired) | Janssen Pharms |
| Concerta | US8163798 | Methods and devices for providing prolonged drug therapy |
Jul 31, 2017
(Expired) | Janssen Pharms |
| Concerta | US8629179 | Methods and devices for providing prolonged drug therapy |
Jul 31, 2017
(Expired) | Janssen Pharms |
| Concerta | US9000038 | Methods and devices for providing prolonged drug therapy |
Jul 31, 2017
(Expired) | Janssen Pharms |
| Concerta | US9029416 | Methods and devices for providing prolonged drug therapy |
Jul 31, 2017
(Expired) | Janssen Pharms |
| Concerta | US9144549 | Methods and devices for providing prolonged drug therapy |
Jul 31, 2017
(Expired) | Janssen Pharms |
| Ritalin La | US5837284 | Delivery of multiple doses of medications |
Dec 04, 2015
(Expired) | Sandoz |
| Ritalin La | US6635284 | Delivery of multiple doses of medications |
Dec 04, 2015
(Expired) | Sandoz |
| Ritalin La | US7431944 | Delivery of multiple doses of medications |
Dec 04, 2015
(Expired) | Sandoz |
A patent's expiry date may change depending upon legal activities going on that patent. Critical
activities like
abandoning of a patent, term extension of a patent or amendment of its claims can increase or
decrease the life of a
patent hence affecting its expiry date and in turn affecting the generic launch date of that
drug. Tracking these
ongoing activities on a patent application helps to keep an eye on the latest developments in
the patent process of
the drug which can give an idea of how early a drug's generic could be available. The next
section provides a list
of recent legal activities on Methylphenidate Hydrochloride's patents.
Latest Legal Activities on Methylphenidate Hydrochloride's Patents
Given below is the list recent legal activities going on the following patents of Methylphenidate Hydrochloride.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Payment of Maintenance Fee, 8th Year, Large Entity | 25 Jun, 2024 | US9545399 |
| Payment of Maintenance Fee, 4th Year, Large Entity | 21 May, 2024 | US10857143 |
| Payment of Maintenance Fee, 12th Year, Large Entity | 03 Apr, 2024 | US8287903(Litigated) |
| Payment of Maintenance Fee, 12th Year, Large Entity | 06 Dec, 2023 | US8202537(Litigated) |
| Payment of Maintenance Fee, 8th Year, Large Entity | 13 Sep, 2023 | US9295642 |
| Mail Miscellaneous Communication to Applicant | 27 Apr, 2023 | US11633389 |
| Electronic Review Critical
| 27 Apr, 2023 | US11633389 |
| Email Notification Critical
| 27 Apr, 2023 | US11633389 |
| Miscellaneous Communication to Applicant - No Action Count | 25 Apr, 2023 | US11633389 |
| Patent Issue Date Used in PTA Calculation Critical
| 25 Apr, 2023 | US11633389 |
Methylphenidate Hydrochloride's Family Patents
Explore Our Curated Drug Screens
Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List